Document Type : Original Article
Authors
1 Assistant Professor Of Nursing, School Of Nursing, Sabzevar University Of Medical Sciences, Sabzevar, Iran
2 Medical Student, School Of Medicine, Sabzevar University Of Medical Sciences, Sabzevar, Iran
3 Phd Student In Medical Education, Department Of Medical Education, Faculty Of Medicine, Shiraz University Of Medical Sciences, Iran
4 Assistant Professor Of Psychiatry, Department Of Internal Medicine, School Of Medicine, Vasei Hospital, Sabzevar University Of Medical Sciences, Sabzevar, Iran
Abstract
Introduction: Olanzapine is one of the first-line antipsychotic drugs for schizophrenia and other mental illnesses. This study aims to determine the effect of Betahistine in preventing weight gain through the use of olanzapine in patients with psychosis.
Materials and Methods: This study was a clinical trial on 120 patients with psychotic disease under standard treatment with olanzapine, after random allocation, 60 people were placed in the intervention and control group. The study data was analyzed using SPSS 24 software and using Wilcoxon and Spearman correlation statistical methods.
Results: The average weight before intervention (control) was 66.3 ± 10.88 kg and after the intervention 69.67 ± 13.03. In the intervention group before the start of the study, it was 66.45 ± 9.95 kg, and after the intervention, 68.16±11.20. The average waist circumference before intervention in the control group was 70.06±12.63 cm and after the intervention 71.55±13.13 cm. In the intervention group, the average waist circumference before the study was 68.26 ± 11.80 cm, and after the intervention, it was obtained to be 69.4 ± 12.70. The results showed that in the inter-group comparison, the amount of weight and waist circumference in the two groups were not statistically significant. In the intra-group comparison, an increase in weight and waist circumference in the two groups was observed after the intervention, which was statistically significant.
Conclusion: The simultaneous use of Betahistine in the intervention group was not effective in weight loss caused by the use of olanzapine. It is recommended to check other methods of weight control in patients taking olanzapine.
Keywords
Main Subjects
- Komossa K, Rummel‐Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews. 2010(3). doi: 10.1002/14651858.CD006654.pub2.
- Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug safety. 2017;40:771-81.DOI: 10.1007/s40264-017-0543-0
- Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PloS one. 2014;9(4):e94112. DOI: 10.1371/journal.pone.0094112
- Correll CU, Joffe BI, Rosen LM, Sullivan TB, Joffe RT. Cardiovascular and cerebrovascular risk factors and events associated with second‐generation antipsychotic compared to antidepressant use in a non‐elderly adult sample: results from a claims‐based inception cohort study. World Psychiatry. 2015;14(1):56-63. DOI: 10.1002/wps.20187
- Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia research. 2004;66(1):51-7. DOI: 10.1016/s0920-9964(02)00498-x
- Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophrenia bulletin. 2013;39(2):295-305. DOI: 10.1093/schbul/sbs082
- Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Perez-Iglesias R, Martinez-Garcia O, Perez-Pardal T, et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. Journal of Clinical Psychiatry. 2006;67(8):1253-60. DOI: 10.4088/jcp.v67n0812
- De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World psychiatry. 2009;8(1):15. doi: 10.1002/j.2051-5545.2009.tb00199.x
- Ali AH, Yanoff LB, Stern EA, Akomeah A, Courville A, Kozlosky M, et al. Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial. The American journal of clinical nutrition. 2010;92(6):1290-7. doi: 10.3945/ajcn.110.001586.Epub 2010 Sep 29.
- Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatric disease and treatment. 2017:2231-41. doi: 10.2147/NDT.S113099
- Zheng W, Zhang Q-E, Cai D-B, Yang X-H, Ungvari GS, Ng CH, et al. Combination of metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2019;52(01):24-31. DOI: 10.1055/s-0044-101466
- Barak N, Beck Y, Albeck JH. A randomized, double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gain. Journal of Clinical Psychopharmacology. 2016;36(3):253-6. DOI: 10.1097/JCP.0000000000000489
- Lee CK, Choi YJ, Park SY, Kim JY, Won KC, Kim YW. Intracerebroventricular injection of metformin induces anorexia in rats. Diabetes & metabolism journal. 2012;36(4):293-9. doi: 10.4093/dmj.2012.36.4.293
- Deng C, Lian J, Pai N, Huang X-F. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. Journal of psychopharmacology. 2012;26(9):1271-9. DOI: 10.1177/0269881112449396
- Barak N, Beck Y, editors. Betahistine safely mitigates olanzapine induced weight gain and sleepiness. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY; 2010: CAMBRIDGE UNIV PRESS 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA. DOI: 10.1177/0269881115626349
- Lian J, Huang X-F, Pai N, Deng C. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS One. 2014;9(8):e104160. DOI: 10.1371/journal.pone.0104160
- Potvin S, Zhornitsky S, Stip E. Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Canadian journal of psychiatry Revue canadienne de psychiatrie. 2015;60(3 Suppl 2):S26.doi: PMC4418620
- Bartoli F, Crocamo C, Clerici M, Carrà G. Second-generation antipsychotics and adiponectin levels in schizophrenia: a comparative meta-analysis. European Neuropsychopharmacology. 2015;25(10):1767-74. DOI: 10.1016/j.euroneuro.2015.06.011
- Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. International clinical psychopharmacology. 2005;20(2):101-3. DOI: 10.1097/00004850-200503000-00007
- Smith RC, Maayan L, Wu R, Youssef M, Jing Z, Sershen H, et al. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology. 2018;235:3545-58. DOI: 10.1002/14651858.CD006654.pub2
)